Baird Financial Group
RXRX icon

Baird Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Baird Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,498
Closed -$76.7K – 1844
2025
Q1 		$76.7K Buy
14,498
+203
+1% +$1.48K ﹤0.01% 1731
2024
Q4 		$96.6K Sell
14,295
-179
-1% -$1.2K ﹤0.01% 1723
2024
Q3 		$95.4K Buy
+14,474
New +$104K ﹤0.01% 1710

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Baird Financial Group's RXRX Position: Q2 2025 in Review

Baird Financial Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 14,498 shares — an estimated $76.7K sold.

Baird Financial Group first reported a position in RXRX in Q3 2024 and held it in 3 quarters. The position peaked at $96.6K in Q4 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Baird Financial Group reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Baird Financial Group sold 14,498 Recursion Pharmaceuticals shares in Q2 2025, an estimated $76.7K.
  • Baird Financial Group first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Baird Financial Group's Recursion Pharmaceuticals position peaked at $96.6K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Baird Financial Group's 13F filing for Q2 2025, filed 13 Aug 2025.